These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 25787305)
21. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Kim KA; Song WG; Lee HM; Joo HJ; Park JY Thromb Res; 2013 Aug; 132(2):221-6. PubMed ID: 23849096 [TBL] [Abstract][Full Text] [Related]
22. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors. Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Baurand A; Raboisson P; Freund M; Léon C; Cazenave JP; Bourguignon JJ; Gachet C Eur J Pharmacol; 2001 Feb; 412(3):213-21. PubMed ID: 11166284 [TBL] [Abstract][Full Text] [Related]
24. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300 [TBL] [Abstract][Full Text] [Related]
25. Potassium 2-(1-hydroxypentyl)-benzoate improves memory deficits and attenuates amyloid and τ pathologies in a mouse model of Alzheimer's disease. Peng Y; Hu Y; Xu S; Rong X; Li J; Li P; Wang L; Yang J; Wang X J Pharmacol Exp Ther; 2014 Aug; 350(2):361-74. PubMed ID: 24893984 [TBL] [Abstract][Full Text] [Related]
26. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro. Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514 [TBL] [Abstract][Full Text] [Related]
27. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Geiger J; Brich J; Hönig-Liedl P; Eigenthaler M; Schanzenbächer P; Herbert JM; Walter U Arterioscler Thromb Vasc Biol; 1999 Aug; 19(8):2007-11. PubMed ID: 10446085 [TBL] [Abstract][Full Text] [Related]
28. Platelet P2Y₁₂ receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng. Gao B; Huang L; Liu H; Wu H; Zhang E; Yang L; Wu X; Wang Z Br J Pharmacol; 2014 Jan; 171(1):214-23. PubMed ID: 24117220 [TBL] [Abstract][Full Text] [Related]
29. Toxicokinetics and toxicity of potassium 2-(1-hydroxypentyl)-benzoate in beagle dogs. Li J; Wang XL; Wang AP; Xu SF; Jin HT J Asian Nat Prod Res; 2017 Apr; 19(4):388-401. PubMed ID: 28367640 [TBL] [Abstract][Full Text] [Related]
30. [Clinical evaluation of platelet antagonists on the ex vivo inhibitory effects of platelet aggregation]. Sakata T; Kobayashi K; Katayama Y; Takada T; Matsuyama T Rinsho Byori; 1991 Mar; 39(3):315-20. PubMed ID: 2051607 [TBL] [Abstract][Full Text] [Related]
31. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. Nooney VB; Hurst NL; Chirkov YY; De Caterina R; Horowitz JD Vascul Pharmacol; 2015; 65-66():17-22. PubMed ID: 25460367 [TBL] [Abstract][Full Text] [Related]
32. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013 [TBL] [Abstract][Full Text] [Related]
34. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131 [TBL] [Abstract][Full Text] [Related]
35. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976 [TBL] [Abstract][Full Text] [Related]
36. Diverse signalling of the platelet P2Y Amison RT; Jamshidi S; Rahman KM; Page CP; Pitchford SC Eur J Pharmacol; 2018 May; 827():58-70. PubMed ID: 29534999 [TBL] [Abstract][Full Text] [Related]
37. Role of P2Y1 purinoceptor in ADP-induced platelet activation. Savi P; Beauverger P; Labouret C; Delfaud M; Salel V; Kaghad M; Herbert JM FEBS Lett; 1998 Feb; 422(3):291-5. PubMed ID: 9498802 [TBL] [Abstract][Full Text] [Related]
38. Pennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways. Cong Y; Liu X; Kang L; Yu Z; Zhao Z; Li J; Ma B; Cong Y Thromb Res; 2012 May; 129(5):e209-16. PubMed ID: 22401797 [TBL] [Abstract][Full Text] [Related]